Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care (BSC) versus BSC alone for advanced UC ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
PrE0807: Neoadjuvant nivolumab without or with lirilumab in cisplatin-ineligible patients with muscle-invasive bladder cancer ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
22 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
Breast cancer roundup from ASCO 2021
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
18 Jun 2021
Real world evidence on the use of antibody drug conjugates in peripheral T-cell ...
Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Leba...
Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )
14 Jun 2021
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC
Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, Fran...
Pembrolizumab improves on chemo in MSI-H/dMMR mCRC ( Prof Thierry André - Sorbonne University and Saint-Antoine Hospital, Paris, France )
11 Jun 2021
CLL14: Venetoclax plus obinutuzumab in untreated CLL
Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany
CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )
11 Jun 2021
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...
Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )
10 Jun 2021
Tislelizumab in oesophageal cancer after systemic therapy
Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA
Tislelizumab in oesophageal cancer after systemic therapy ( Dr Jaffer Ajani - The University of Texas MD Anderson Cancer Center, Texas, USA )
9 Jun 2021
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with sel...
Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
9 Jun 2021